A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

NCT04533490 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Resectable Esophageal Squamous Cell Carcinoma

Interventions

DRUG: SHR-1210

Sponsor

The First Affiliated Hospital of Zhengzhou University